SCHEMBL7180865

SCHEMBL7180865

CCOc1cc(OCC)c(PC(=O)c2c(C(F)(F)F)cccc2C(F)(F)F)c(OCC)c1.[LiH]

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 1/20 0.43
KCNK9 Q9NPC2 1/20 0.43
KMT2A Q03164 3/20 0.41
RXRA P19793 2/20 0.41
RXRB P28702 2/20 0.41
RXRG P48443 2/20 0.41
KDM4E B2RXH2 2/20 0.41
TP53 P04637 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
MEN1 O00255 2/20 0.36
LMNA P02545 1/20 0.36
PAX8 Q06710 1/20 0.36
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
ALOX12 P18054 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7177721 0.88 KMT2A (0.39) KCNK3KCNK9KMT2AL3MBTL1LMNA
SCHEMBL7183985 0.88 L3MBTL1 (0.38) KCNK3KCNK9KMT2ARXRARXRB
SCHEMBL7182741 0.87 FAAH (0.41) CYP1A2CYP2C9CYP2C19
SCHEMBL7182209 0.86 THRA (0.41) CYP1A2CYP2C19
SCHEMBL7184698 0.86 KDM4E (0.42) KCNK3KCNK9KMT2ARXRARXRB
SCHEMBL7181224 0.85 THRA (0.43)
SCHEMBL7177796 0.85 HTT (0.39) KCNK3KCNK9KMT2AKDM4ERXFP1
SCHEMBL7180750 0.85 FOS (0.38) MRGPRX4HPGD
Lithium SCHEMBL7184703 0.83 KDM4E (0.42) KCNK3KCNK9KMT2ARXRARXRB
SCHEMBL7189117 0.83 PDK2 (0.39) CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KCNK3 351/4885KCNK9 352/4885KMT2A 1586/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KCNK3 388/4885KCNK9 553/4885KMT2A 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.